Compare OESX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OESX | ATOS |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 36.2M |
| IPO Year | 2007 | 2010 |
| Metric | OESX | ATOS |
|---|---|---|
| Price | $9.12 | $5.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $17.50 | ★ $23.00 |
| AVG Volume (30 Days) | 33.8K | ★ 51.8K |
| Earning Date | 02-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $79,720,000.00 | $1,758.00 |
| Revenue This Year | $7.94 | N/A |
| Revenue Next Year | $13.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.53 |
| 52 Week High | $18.64 | $7.56 |
| Indicator | OESX | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 53.42 |
| Support Level | $8.80 | $0.66 |
| Resistance Level | $10.20 | $5.56 |
| Average True Range (ATR) | 0.61 | 0.34 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 26.54 | 50.97 |
Orion Energy Systems Inc is engaged in light-emitting diode lighting systems, wireless Internet of Things-enabled control solutions, project engineering, energy project management design, maintenance services, and turnkey electric vehicle charging stations and related installation services to commercial and industrial businesses, and federal and local governments, predominantly in North America. The group has three segments: the Orion lighting segment, the Orion maintenance segment, and the Orion electric vehicle charging segment. It generates the majority of its revenue from the Orion lighting segment, which develops and sells lighting products and provides construction and engineering services for Orion's commercial lighting and energy management systems.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.